Form 4: Tyra Biosciences Director Stephen Rothenberg Granted 22,200 Stock Options

Tyra Biosciences, Inc. Director Stephen Michael Rothenberg was granted 22,200 stock options as part of the company's Non-Employee Director Compensation Program.

Summary

• Stephen Michael Rothenberg, a Director of Tyra Biosciences, Inc. (TYRA), was granted 22,200 stock options on May 29, 2025.
• The stock options have an exercise price of $9.25 per share.
• These options were granted under the Issuer's Non-Employee Director Compensation Program.
• The options will vest monthly, with 1/12th of the total shares vesting each month following the grant date of May 29, 2025.
• An accelerated vesting clause states that any remaining unvested portion will vest on the date of the next annual meeting of stockholders if it occurs prior to the first anniversary of the grant date, subject to continuous service.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Stephen Michael Rothenberg beneficially owns 22,200 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is a standard part of director compensation. It aligns director interests with shareholders, which is mildly positive, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard component of non-employee director compensation, indicating a structured approach to governance and incentive alignment.

Future Outlook

The vesting schedule of the stock options, which extends monthly following the grant date and includes a potential accelerated vesting upon the next annual meeting, implies an expectation of continued service from the director.

Management Comments

• The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain experienced board members and align their incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of a non-employee director compensation program is a standard industry practice, comparable to compensation structures seen in other publicly traded biotechnology companies.
• The vesting schedule, which includes monthly vesting and potential acceleration, is typical for such grants, aiming to ensure continued engagement and long-term commitment from the director.

Corporate Governance

Related Party Transactions

• The grant of 22,200 stock options to Stephen Michael Rothenberg, a director of Tyra Biosciences, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's financial interests with those of the shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting employees, the compensation structure for directors reflects the company's overall approach to incentivizing key personnel.

Next Steps

• The stock options will continue to vest monthly, subject to Stephen Michael Rothenberg's continuous service to Tyra Biosciences, Inc.

Key Dates

Recommendation

Keywords

Tyra Biosciences, TYRA, Stephen Michael Rothenberg, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corporate Governance